Hideho Okada, MD, PhD
Professor
Neurological Surgery
School of Medicine

Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. Dr. Okada's success in navigating the detailed regulatory processes required for such trials demonstrates his attention to detail and breadth of knowledge, spanning from basic science to clinical care. Dr. Okada's lab work was the first to identify and fully characterize cytotoxic T-lymphocyte (CTL) epitopes for gliomas. Dr. Okada's seminal discovery of CTL epitopes in glioma-associated antigens and the work on the mechanisms underlying the adjuvant effects of poly-ICLC enabled him to launch novel glioma vaccine trials in combination with poly-ICLC as an adjuvant. These efforts have also been supported by his mechanistic studies delineating the role of an integrin receptor very late activation antigen (VLA)-4 and chemokine CXCL10 in the efficient trafficking of T-cells to brain tumor sites. Dr. Okada has held 10 Investigational New Drug approvals that the FDA approved for early-phase clinical trials, including genetically engineered glioma vaccines and T cell receptor (TCR)- or chimeric antigen receptor (CAR)-transduced T cell therapy in both adult and pediatric patients. For example, Dr. Okada has developed a chimeric antigen receptor (CAR) against epidermal growth factor receptor (EGFR)vIII, which has been evaluated in patients with EGFRvIII+ GBM. Recently, Dr. Okada developed a novel synNotch-primed CAR system with Dr. Wendell Lim to overcome the antigen-heterogeneity, off-tumor toxicity, and T-cell exhaustion issues. Dr. Okada’s team has also pioneered discoveries of novel immunoregulatory mechanisms in gliomas, such as one mediated by myeloid-derived suppressor cells (MDSC) and mutations of the isocitrate dehydrogenase (IDH)1 and IDH2. As a thought leader, to improve radiologic evaluation criteria for patients undergoing immunotherapy, Dr. Okada led an international group of brain tumor immunotherapy experts to develop novel Immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria. Dr. Okada is an elected member of the American Society for Clinical Investigation (2010-present), an honored society for physicians who promote laboratory science to the clinic. Dr. Okada also serves as an Associate Editor for Neuro-Oncology, the most prominent journal for brain tumor research.

• Glioma-neuronal circuit remodeling induces regional immunosuppression.
  Nature communications 2025 Nejo T, Krishna S, Yamamichi A, Lakshmanachetty S, Jimenez C, Lee KY, Baker DL, Young JS, Chen T, Phyu SSS, Phung L, Gallus M, Maldonado GC, Okada K, Ogino H, Watchmaker PB, Diebold D, Choudhury A, …
• Closed-loop sonothermogenetic control of CAR T cells for metronomic brain cancer therapy.
  bioRxiv : the preprint server for biology 2025 Zamat A, Kim C, Sridhar S, Fabrega S, Sen R, Campbell N, Oliver SA, Zha Z, Thiveaud C, Kulaksizoglu E, Brienen M, Okada H, Woodworth GF, Arvanitis C, Kwong GA
• Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model.
  Neuro-oncology advances 2025 Hatae R, Watchmaker PB, Yamamichi A, Kyewalabye K, Okada K, Phyu S, Goretsky Y, Haegelin J, Pineo-Cavanaugh P, Gallus M, Phung L, Chen T, Long H, Chuntova P, Raulet DH, Terabe M, Okada H
• Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.
  bioRxiv : the preprint server for biology 2025 Piyadasa H, Oberlton B, Ribi M, Ranek JS, Averbukh I, Leow K, Amouzgar M, Liu CC, Greenwald NF, McCaffrey EF, Kumar R, Ferrian S, Tsai AG, Filiz F, Fullaway CC, Bosse M, Varra SR, Kong A, Sowers C, …
• Tumour-wide RNA splicing aberrations generate actionable public neoantigens.
  Nature 2025 Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Liu J, Wu SH, Ramos E, Yamamichi A, Watchmaker PB, Ogino …
• Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
  Neuro-oncology 2025 Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H
• Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review.
  JAMA neurology 2025 Ismail FS, Gallus M, Meuth SG, Okada H, Hartung HP, Melzer N
• Programming tissue-sensing T cells that deliver therapies to the brain.
  Science (New York, N.Y.) 2024 Simic MS, Watchmaker PB, Gupta S, Wang Y, Sagan SA, Duecker J, Shepherd C, Diebold D, Pineo-Cavanaugh P, Haegelin J, Zhu R, Ng B, Yu W, Tonai Y, Cardarelli L, Reddy NR, Sidhu SS, Troyanskaya O, Hauser…
• Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
  Neuro-oncology 2024 Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H
• IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
  Neuro-oncology 2024 Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, Guemes M, Galic Z, Phyu S, Okada H, Grausam KB, Breunig JJ, Brown CE, Nathanson DA, Prins RM, Chen YY
• Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System.
  Journal of visualized experiments : JoVE 2024 Kim K, Gallus M, Xiao T, Parchure AS, Shah BR, Okada H, Diederich C, Ozhinsky E, Narsinh K
• Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier.
  Nature communications 2024 Guo Y, Lee H, Kim C, Park C, Yamamichi A, Chuntova P, Gallus M, Bernabeu MO, Okada H, Jo H, Arvanitis C
• Activating the dark genome to illuminate cancer vaccine targets.
  Nature genetics 2024 Kwok DW, Okada H, Costello JF
• Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas?
  Vaccines 2024 Phung LH, Nejo T, Okada H
• Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024 Kotecha R, Schiff D, Chakravarti A, Fleming JL, Brown PD, Puduvalli VK, Vogelbaum MA, Gondi V, Gallus M, Okada H, Mehta MP
• A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
  Cells 2024 Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H
• Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment.
  JCI insight 2024 Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H
• IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
  bioRxiv : the preprint server for biology 2024 Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H
• Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma.
  Scientific reports 2024 Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker PB, Naik A, Shai A, Phillips JJ, Chang …
• Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.
  The Journal of clinical investigation 2024 Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY
• A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
  Neuro-oncology 2024 Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, …
• Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective.
  Cell 2024 Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, Grishanina NR, Kwok D, Stevers NO, Jin Q, Youngblood MW, Stasiak LA, Hou Y, Wang J, Yamaguchi TN, Lafontaine M, Shai A, Smirnov IV, Solomon DA, …
• Glioblastoma vaccines: past, present, and opportunities.
  EBioMedicine 2024 Xiong Z, Raphael I, Olin M, Okada H, Li X, Kohanbash G
• Correction: Gallus et al. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma. Cancers 2023, 15, 3726.
  Cancers 2023 Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H
• A road map for the treatment of pediatric diffuse midline glioma.
  Cancer cell 2023 Koschmann C, Al-Holou WN, Alonso MM, Anastas J, Bandopadhayay P, Barron T, Becher O, Cartaxo R, Castro MG, Chung C, Clausen M, Dang D, Doherty R, Duchatel R, Dun M, Filbin M, Franson A, Galban S, …
• Enhancing CAR-T Cell Metabolism to Overcome Hypoxic Conditions in the Brain Tumor Microenvironment.
  bioRxiv : the preprint server for biology 2023 Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H
• Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma.
  bioRxiv : the preprint server for biology 2023 Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker P, Naik A, Shai A, Phillips JJ, Chang …
• Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens.
  bioRxiv : the preprint server for biology 2023 Kwok DW, Stevers NO, Nejo T, Chen LH, Etxeberria I, Jung J, Okada K, Cove MC, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Wu SH, Ramos E, Yamamichi A, Liu J, Watchmaker P, Ogino H, …
• Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect.
  Neuro-oncology advances 2023 Gibson D, Ravi A, Rodriguez E, Chang S, Oberheim Bush N, Taylor J, Clarke J, Solomon D, Scheffler A, Witte J, Lambing H, Okada H, Berger M, Chehab F, Butowski NA
• Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma.
  Cancer discovery 2023 Lee J, Nicosia M, Hong ES, Silver DJ, Li C, Bayik D, Watson DC, Lauko A, Kay KE, Wang SZ, Johnson S, McGraw M, Grabowski MM, Kish DD, Desai AB, Goodman WA, Cameron SJ, Okada H, Valujskikh A, Fairchild…
• Glioma-neuronal circuit remodeling induces regional immunosuppression.
  bioRxiv : the preprint server for biology 2023 Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H
• Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.
  Cancers 2023 Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H
• Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell-mediated limbic encephalitis.
  Science advances 2023 Gallus M, Roll W, Dik A, Barca C, Zinnhardt B, Hicking G, Mueller C, Naik VN, Anstötz M, Krämer J, Rolfes L, Wachsmuth L, Pitsch J, van Loo KMJ, Räuber S, Okada H, Wimberley C, Strippel C, Golombeck …
• Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al.
  Journal for immunotherapy of cancer 2023 Chheda ZS, Mueller S, Hegde B, Yamamichi A, Butterfield LH, Okada H
• Magnetic Resonance Spectroscopy Metabolites as Biomarkers of Disease Status in Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Treated with Glioma-Associated Antigen Peptide Vaccines.
  Cancers 2022 Panigrahy A, Jakacki RI, Pollack IF, Ceschin R, Okada H, Nelson MD, Kohanbash G, Dhall G, Bluml S
• RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
  Nature 2022 Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, …
• Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2022 Shin J, Parker MFL, Zhu I, Alanizi A, Rodriguez CI, Liu R, Watchmaker PB, Kalita M, Blecha J, Luu J, Wright B, Lapi SE, Flavell RR, Okada H, Tlsty TD, Roybal KT, Wilson DM
• Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma.
  Current opinion in oncology 2022 Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H
• Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
  The Journal of clinical investigation 2022 Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, …
• The future of cancer immunotherapy for brain tumors: a collaborative workshop.
  Journal of translational medicine 2022 Brown CE, Bucktrout S, Butterfield LH, Futer O, Galanis E, Hormigo A, Lim M, Okada H, Prins R, Marr SS, Tanner K
• Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
  Journal for immunotherapy of cancer 2022 Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H
• Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
  Neuro-oncology 2022 Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H
• Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
  The Journal of clinical investigation 2022 Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, …
• The immunology of low-grade gliomas.
  Neurosurgical focus 2022 Haddad AF, Young JS, Oh JY, Okada H, Aghi MK
• The current landscape of immunotherapy for pediatric brain tumors.
  Nature cancer 2022 Hwang EI, Sayour EJ, Flores CT, Grant G, Wechsler-Reya R, Hoang-Minh LB, Kieran MW, Salcido J, Prins RM, Figg JW, Platten M, Candelario KM, Hale PG, Blatt JE, Governale LS, Okada H, Mitchell DA, …
• Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
  Journal for immunotherapy of cancer 2021 Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, Shahani SA, Wang LD, Brown CE, Walker PR, …
• IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity.
  Journal for immunotherapy of cancer 2021 Ohkuri T, Kosaka A, Ikeura M, Salazar AM, Okada H
• SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.
  Science translational medicine 2021 Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS…
• Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
  Neuro-oncology 2021 Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, …
• Current Advances in Immunotherapy for Glioblastoma.
  Current oncology reports 2021 Mende AL, Schulte JD, Okada H, Clarke JL
• The evolution of alternative splicing in glioblastoma under therapy.
  Genome biology 2021 Wang L, Shamardani K, Babikir H, Catalan F, Nejo T, Chang S, Phillips JJ, Okada H, Diaz AA
• Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with 19F MRI in a Murine Model.
  Radiology. Imaging cancer 2021 Chapelin F, Leach BI, Chen R, Lister D, Messer K, Okada H, Ahrens ET
• Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade.
  JCI insight 2021 Nair S, Mazzoccoli L, Jash A, Govero J, Bais SS, Hu T, Fontes-Garfias CR, Shan C, Okada H, Shresta S, Rich JN, Shi PY, Diamond MS, Chheda MG
• Considerations when treating high-grade pediatric glioma patients with immunotherapy.
  Expert review of neurotherapeutics 2020 Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada H
• Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.
  The Journal of clinical investigation 2020 Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, …
• The current state of immunotherapy for primary and secondary brain tumors: similarities and differences.
  Japanese journal of clinical oncology 2020 Nejo T, Mende A, Okada H
• The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
  Journal for immunotherapy of cancer 2020 Ascierto PA, Bifulco C, Galon J, Garbe C, Khleif SN, McQuade J, Odunsi K, Okada H, Paulos CM, Quezada SA, Tawbi HA, Timmerman J, Trinchieri G, Butterfield LH, Puzanov I
• T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
  Journal of neuro-oncology 2020 Kwok D, Okada H
• Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.
  Neuro-oncology practice 2020 Montoya ML, Kasahara N, Okada H
• Tumor antigens in glioma.
  Seminars in immunology 2020 Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H
• Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.
  Nature communications 2020 Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M
• Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).
  Journal for immunotherapy of cancer 2019 Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, …
• Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy.
  Journal of neuro-oncology 2019 Alcaide-Leon P, Luks TL, Lafontaine M, Lupo JM, Okada H, Clarke JL, Villanueva-Meyer JE
• Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection.
  Magnetic resonance in medicine 2019 Hingorani DV, Chapelin F, Stares E, Adams SR, Okada H, Ahrens ET
• Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
  Molecular & cellular proteomics : MCP 2019 Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit…
• Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.
  Molecular & cellular proteomics : MCP 2019 Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit…
• The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion.
  Journal for immunotherapy of cancer 2019 Pinton L, Masetto E, Vettore M, Solito S, Magri S, D'Andolfi M, Del Bianco P, Lollo G, Benoit JP, Okada H, Diaz A, Della Puppa A, Mandruzzato S
• Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
  Nature 2019 Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, …
• Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
  Frontiers in immunology 2019 Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H
• Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.
  World neurosurgery 2019 Young JS, Dayani F, Morshed RA, Okada H, Aghi MK
• Actively personalized vaccination trial for newly diagnosed glioblastoma.
  Nature 2018 Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon …
• Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.
  Oncoimmunology 2018 Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, Dietrich PY, Okada H, Walker PR
• Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
  Molecular & cellular proteomics : MCP 2018 Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit…
• Immunotherapy of Primary Brain Tumors: Facts and Hopes.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Buerki RA, Chheda ZS, Okada H
• Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas.
  JCI insight 2018 Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G
• Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.
  Genome biology 2017 Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A
• Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model.
  Scientific reports 2017 Chapelin F, Gao S, Okada H, Weber TG, Messer K, Ahrens ET
• Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
  The Journal of experimental medicine 2017 Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, …
• Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.
  Oncoimmunology 2017 Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY
• A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
  Science translational medicine 2017 O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada…
• Is the immune response a friend or foe for viral therapy of glioma?
  Neuro-oncology 2017 Okada H, Thorne SH
• Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
  The Journal of clinical investigation 2017 Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H
• Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
  Oncogene 2017 Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK
• Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.
  Neuroimaging clinics of North America 2017 Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A
• Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study.
  Journal of neuro-oncology 2016 Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H
• Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
  Journal of neuro-oncology 2016 Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H
• Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.
  Scientific reports 2016 Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM
• Cellular immunotherapy for malignant gliomas.
  Expert opinion on biological therapy 2016 Lin Y, Okada H
• IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
  Neuro-oncology 2016 Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N
• Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas.
  Neuro-oncology 2016 Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H
• Prioritization schema for immunotherapy clinical trials in glioblastoma.
  Oncoimmunology 2016 Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA,…
• The role of emerging therapy in the management of patients with diffuse low grade glioma.
  Journal of neuro-oncology 2015 Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ
• Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
  The Lancet. Oncology 2015 Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen …
• Principles of immunology and its nuances in the central nervous system.
  Neuro-oncology 2015 Dunn GP, Okada H
• Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas.
  Oncoimmunology 2015 Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H
• Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival.
  Oncoimmunology 2015 Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL
• Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.
  Journal of neuro-oncology 2015 Reardon DA, Okada H
• Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
  Science translational medicine 2015 Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell…
• Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.
  Biochemical and biophysical research communications 2015 Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H
• Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy.
  Oncoimmunology 2015 Ohkuri T, Ghosh A, Kosaka A, Sarkar SN, Okada H
• Classification of current anticancer immunotherapies.
  Oncotarget 2014 Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, …
• CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.
  Journal for immunotherapy of cancer 2014 Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR
• Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS
• STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment.
  Cancer immunology research 2014 Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, Watkins SC, Sarkar SN, Okada H
• Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H
• Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.
  Cancer immunology, immunotherapy : CII 2014 Kosaka A, Ohkuri T, Okada H
• Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.
  Journal for immunotherapy of cancer 2013 Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, Okada H
• Immune-checkpoint blockade and active immunotherapy for glioma.
  Cancers 2013 Ahn BJ, Pollack IF, Okada H
• Ependymomas: development of immunotherapeutic strategies.
  Expert review of neurotherapeutics 2013 Pollack IF, Jakacki RI, Butterfield LH, Okada H
• GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α.
  Cancer research 2013 Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H
• Peptide vaccine therapy for childhood gliomas.
  Neurosurgery 2013 Pollack IF, Jakacki RI, Butterfield LH, Okada H
• In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging.
  PloS one 2013 Zhong J, Sakaki M, Okada H, Ahrens ET
• Integration of epidemiology, immunobiology, and translational research for brain tumors.
  Annals of the New York Academy of Sciences 2013 Okada H, Scheurer ME, Sarkar SN, Bondy ML
• Premetastatic soil and prevention of breast cancer brain metastasis.
  Neuro-oncology 2013 Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H
• LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H
• Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy.
  Journal of neuro-oncology 2012 Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF
• Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus.
  Advances in virology 2012 Reinhart B, Mazzacurati L, Forero A, Hong CS, Eguchi J, Okada H, Fellows W, Niranjan A, Cohen JB, Glorioso JC, Grandi P
• Differential activity of interferon-α8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma.
  Oncoimmunology 2012 Kohanbash G, Ishikawa E, Fujita M, Ikeura M, McKaveney K, Zhu J, Sakaki M, Sarkar SN, Okada H
• Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
  Journal of translational medicine 2012 Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I
• Type17 T-cells in central nervous system autoimmunity and tumors.
  Journal of clinical immunology 2012 Okada H, Khoury SJ
• Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.
  Cytotherapy 2012 Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T
• Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
  Journal of immunology (Baltimore, Md. : 1950) 2012 Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ
• Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development.
  Immunological investigations 2012 Kohanbash G, Okada H
• MicroRNAs and STAT interplay.
  Seminars in cancer biology 2011 Kohanbash G, Okada H
• Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.
  Cancer immunology, immunotherapy : CII 2011 Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H
• Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
  Immunologic research 2011 Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL
• Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.
  The Journal of clinical investigation 2011 Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY
• Do we need novel radiologic response criteria for brain tumor immunotherapy?
  Expert review of neurotherapeutics 2011 Okada H, Pollack IF
• COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
  Cancer research 2011 Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H
• Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack …
• Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
  Journal of neuro-oncology 2010 Zhu X, Fujita M, Snyder LA, Okada H
• Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
  Cancer immunology, immunotherapy : CII 2010 Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H
• Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H
• A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice.
  PloS one 2010 Steitz J, Barlow PG, Hossain J, Kim E, Okada K, Kenniston T, Rea S, Donis RO, Gambotto A
• Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
  Seminars in immunology 2010 Kalinski P, Okada H
• miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.
  Journal of translational medicine 2010 Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H
• MicroRNAs in immune regulation--opportunities for cancer immunotherapy.
  The international journal of biochemistry & cell biology 2010 Okada H, Kohanbash G, Lotze MT
• Balb/c EGFP mice are tolerant against immunization utilizing recombinant adenoviral-based vectors encoding EGFP: a novel model for the study of tolerance mechanisms and vaccine efficacy.
  Molecular immunology 2009 Steitz J, Soloff AC, Barratt-Boyes SM, Alber SM, Watkins SC, Okada H, Gambotto A
• Immunotherapy for pediatric central nervous system tumors.
  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009 Gardner SL, Ahmed N, Okada H
• Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H
• IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2009 Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ
• Brain tumor immunotherapy with type-1 polarizing strategies.
  Annals of the New York Academy of Sciences 2009 Okada H
• Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.
  Proceedings of the National Academy of Sciences of the United States of America 2009 Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H
• Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.
  Cancer gene therapy 2009 Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ
• Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.
  Cancer research 2009 Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H
• Immunotherapeutic approaches for glioma.
  Critical reviews in immunology 2009 Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M
• IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit.
  European journal of immunology 2008 Sasaki K, Pardee AD, Okada H, Storkus WJ
• Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.
  Journal of immunology (Baltimore, Md. : 1950) 2008 Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ
• Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas.
  Journal of neuro-oncology 2008 Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF
• Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
  Journal of immunology (Baltimore, Md. : 1950) 2008 Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H
• Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
  Journal of translational medicine 2007 Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC, …
• Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
  Journal of translational medicine 2007 Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H
• Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.
  Cancer research 2007 Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, …
• Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.
  Cancer research 2007 Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H
• Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
  Journal of immunology (Baltimore, Md. : 1950) 2007 Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ
• Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
  Journal of translational medicine 2007 Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H
• Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, Ma W, Hoa N, Minev B, Delgado C, Wepsic HT, Okada H, Jadus MR
• Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis.
  Methods in molecular biology (Clifton, N.J.) 2007 MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J
• Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
  Cancer research 2006 Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H
• Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
  Cancer research 2006 Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H
• Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors.
  Cancer gene therapy 2005 Sato H, Kuwashima N, Sakaida T, Hatano M, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Okada H
• Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H
• EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.
  Neoplasia (New York, N.Y.) 2005 Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H
• IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity.
  Journal of immunology (Baltimore, Md. : 1950) 2005 Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H
• [Immunotherapy for brain tumor: don't get "Lost in Translation"].
  No shinkei geka. Neurological surgery 2005 Okada H
• The characterization of tumor apoptosis after experimental radiosurgery.
  Stereotactic and functional neurosurgery 2005 Witham TF, Okada H, Fellows W, Hamilton RL, Flickinger JC, Chambers WH, Pollack IF, Watkins SC, Kondziolka D
• Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors.
  Journal of translational medicine 2004 Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H
• Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
  Gene therapy 2004 Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H
• Cytokine gene therapy for malignant glioma.
  Expert opinion on biological therapy 2004 Okada H, Pollack IF
• Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
  Cancer research 2004 Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF
• Biologic therapy for brain cancers--based on cellular and immunobiology.
  Yonsei medical journal 2004 Okada H
• Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
  Cancer research 2003 Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ
• Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.
  Journal of neuro-oncology 2003 Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, Elder EH, Whiteside TL, Schold SC, Pollack IF
• Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.
  Journal of neuro-oncology 2003 Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH
• Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells.
  Cancer gene therapy 2003 Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H
• Gene therapy and biologic therapy with interleukin-4.
  Current gene therapy 2002 Okada H, Kuwashima N
• Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H
• 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model.
  Neurosurgery 2002 Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF
• Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas.
  Cancer research 2002 Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, Kondziolka D, Okada H, Pollack IF, Chambers WH
• Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors.
  Journal of neurosurgery 2001 Nakahara N, Okada H, Witham TF, Attanucci J, Fellows WK, Chambers WH, Niranjan A, Kondziolka D, Pollack IF
• Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
  Gene therapy 2001 Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH
• Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response.
  Human gene therapy 2001 Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D, Attanucci J, Edington H, Chambers W, Kalinski P, Kinzler D, Whiteside T, Elder E, Potter D
• Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
  Cancer research 2001 Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH
• Exploitation of immune mechanisms in the treatment of central nervous system cancer.
  Seminars in pediatric neurology 2000 Pollack IF, Okada H, Chambers WH
• Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
  Cancer research 2000 Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH
• Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.
  Cancer gene therapy 2000 Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT
• Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response.
  Human gene therapy 2000 Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E
• Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.
  The cancer journal from Scientific American 2000 Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM, Whiteside TL, Elder EM, Okada H, Robbins P
• Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.
  Gene therapy 1999 Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME
• [Neurosurgery and molecular biology: (series 10) gene therapy and biological therapy for brain tumors].
  No shinkei geka. Neurological surgery 1999 Okada H
• Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.
  International journal of cancer 1998 Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME